PMID- 35795862 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20220718 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2022 DP - 2022 TI - Cystathionine beta-Synthase Regulates the Proliferation, Migration, and Invasion of Thyroid Carcinoma Cells. PG - 8678363 LID - 10.1155/2022/8678363 [doi] LID - 8678363 AB - Thyroid cancer is considered to be one of the most common endocrine tumors worldwide. Cystathionine beta-synthase (CBS) plays a crucial role in the occurrence of several types of malignancies. And yet, the mechanism of action of CBS in the growth of thyroid carcinoma cells is still unrevealed. We found that CBS level in thyroid carcinoma tissue was higher than that in adjacent normal tissue. The overexpression of CBS enhanced the proliferation, migration, and invasion of thyroid cancer cells, while the downregulation of CBS exerted reverse effects. CBS overexpression reduced the levels of cleaved caspase-3 and cleaved poly ADP-ribose polymerase in thyroid cancer cells, whereas CBS knockdown showed reverse trends. CBS overexpression decreased reactive oxygen species (ROS) levels but increased the levels of Wnt3a and phosphorylations of phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT), mammalian target of rapamycin (mTOR), beta-catenin, and glycogen synthase kinase-3 beta, while CBS knockdown exerted opposite effects. In addition, CBS overexpression promoted the growth of xenografted thyroid carcinoma, whereas CBS knockdown decreased the tumor growth by modulating angiogenesis, cell cycle, and apoptosis. Furthermore, aminooxyacetic acid (an inhibitor of CBS) dose-dependently inhibited thyroid carcinoma cell growth. CBS can regulate the proliferation, migration, and invasion of human thyroid cancer cells via ROS-mediated PI3K/AKT/mTOR and Wnt/beta-catenin pathways. CBS can be a potential biomarker for diagnosing or prognosing thyroid carcinoma. Novel donors that inhibit the expression of CBS can be developed in the treatment of thyroid carcinoma. CI - Copyright (c) 2022 Qi-Ying Jiang et al. FAU - Jiang, Qi-Ying AU - Jiang QY AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Li, Jian-Mei AU - Li JM AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Jing, Mi-Rong AU - Jing MR AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Zhang, Yan-Xia AU - Zhang YX AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Zhang, Qian-Qian AU - Zhang QQ AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Cai, Chun-Bo AU - Cai CB AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Wang, Di AU - Wang D AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Qi, Hui-Wen AU - Qi HW AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Li, Tao AU - Li T AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Li, Yan-Zhang AU - Li YZ AUID- ORCID: 0000-0002-7327-0015 AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. FAU - Ji, Xin-Ying AU - Ji XY AUID- ORCID: 0000-0003-0690-4206 AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. AD - Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan 475004, China. FAU - Wu, Dong-Dong AU - Wu DD AUID- ORCID: 0000-0001-6739-8437 AD - School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China. AD - Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China. AD - School of Stomatology, Henan University, Kaifeng, Henan 475004, China. LA - eng PT - Journal Article DEP - 20220627 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 RN - 0 (Reactive Oxygen Species) RN - 0 (beta Catenin) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 4.2.1.22 (Cystathionine beta-Synthase) SB - IM MH - Cell Proliferation/physiology MH - *Cystathionine beta-Synthase/metabolism MH - Humans MH - Phosphatidylinositol 3-Kinases/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - Reactive Oxygen Species/metabolism MH - TOR Serine-Threonine Kinases/metabolism MH - *Thyroid Neoplasms/enzymology/pathology MH - beta Catenin/metabolism PMC - PMC9252770 COIS- The authors declare that they have no competing interests. EDAT- 2022/07/08 06:00 MHDA- 2022/07/09 06:00 PMCR- 2022/06/27 CRDT- 2022/07/07 02:38 PHST- 2022/01/17 00:00 [received] PHST- 2022/04/17 00:00 [revised] PHST- 2022/05/24 00:00 [accepted] PHST- 2022/07/07 02:38 [entrez] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/06/27 00:00 [pmc-release] AID - 10.1155/2022/8678363 [doi] PST - epublish SO - Oxid Med Cell Longev. 2022 Jun 27;2022:8678363. doi: 10.1155/2022/8678363. eCollection 2022.